ES2150378A1 - Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. - Google Patents

Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Info

Publication number
ES2150378A1
ES2150378A1 ES009801708A ES9801708A ES2150378A1 ES 2150378 A1 ES2150378 A1 ES 2150378A1 ES 009801708 A ES009801708 A ES 009801708A ES 9801708 A ES9801708 A ES 9801708A ES 2150378 A1 ES2150378 A1 ES 2150378A1
Authority
ES
Spain
Prior art keywords
troubles
group
heteroaryl
mediated
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009801708A
Other languages
English (en)
Other versions
ES2150378B1 (es
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to ES009801708A priority Critical patent/ES2150378B1/es
Priority to ARP990103870A priority patent/AR019999A1/es
Priority to CO99049291A priority patent/CO5080747A1/es
Priority to CA002339661A priority patent/CA2339661C/en
Priority to CZ2001412A priority patent/CZ292065B6/cs
Priority to BR9912807-1A priority patent/BR9912807A/pt
Priority to PT99940199T priority patent/PT1103243E/pt
Priority to DK99940199T priority patent/DK1103243T3/da
Priority to AU54229/99A priority patent/AU754124B2/en
Priority to PCT/ES1999/000255 priority patent/WO2000007542A2/es
Priority to TW088113353A priority patent/TW445259B/zh
Priority to EP99940199A priority patent/EP1103243B1/en
Priority to KR1020017001560A priority patent/KR100558506B1/ko
Priority to CNB998109150A priority patent/CN1151789C/zh
Priority to HU0105428A priority patent/HUP0105428A3/hu
Priority to NZ509645A priority patent/NZ509645A/xx
Priority to PL99346221A priority patent/PL193802B1/pl
Priority to AT99940199T priority patent/ATE257379T1/de
Priority to ES99940199T priority patent/ES2213380T3/es
Priority to US09/762,079 priority patent/US6518295B1/en
Priority to DE69914085T priority patent/DE69914085T8/de
Priority to TR2001/00378T priority patent/TR200100378T2/xx
Priority to RU2001106644/15A priority patent/RU2223116C2/ru
Priority to JP2000563228A priority patent/JP2002522359A/ja
Publication of ES2150378A1 publication Critical patent/ES2150378A1/es
Priority to ZA200100867A priority patent/ZA200100867B/en
Priority to NO20010634A priority patent/NO20010634L/no
Priority to IL14129501A priority patent/IL141295A0/xx
Application granted granted Critical
Publication of ES2150378B1 publication Critical patent/ES2150378B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboración de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia P. Los derivados de aril(o heteroaril)azolilcarbinol (I) donde Ar es fenilo o tienilo opcionalmente sustituidos, R{sub,1 -C{sub,4 , R{sub,2 es H, dialquilaminoalquilo,alquilazaheterociclilalquilo o azaheterociclilalquilo, y Het es un heterociclo aromático nitrogenado de 5 miembros que contiene de 1 a 3 átomos de nitrógeno, opcionalmente sustituido, son útiles para el tratamiento de los trastornos que vienen mediados por un exceso de substancia P, especialmente, ciertos trastornos del sistema nervioso central tales como ansiedad, depresión, esquizofrenia, psicosis maníaco depresiva, disfunción sexual, drogodependencias, trastornos cognitivos, trastornos locomotores, etc., en mamíferos, incluidos el hombre.
ES009801708A 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. Expired - Fee Related ES2150378B1 (es)

Priority Applications (27)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
CO99049291A CO5080747A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
ARP990103870A AR019999A1 (es) 1998-08-07 1999-08-04 Empleo de derivados de aril(heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso desustancia p.
ES99940199T ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.
BR9912807-1A BR9912807A (pt) 1998-08-07 1999-08-05 Uso de derivados de arila (ou heteroarila) azolilcarbinol na fabricação de medicamento para tratamento de distúrbios mediados por excesso de substância p
PT99940199T PT1103243E (pt) 1998-08-07 1999-08-05 Utilizacao de derivados aril(ou heteroaril)azolilcarbinol na preparacao de um medicamento para o tratamento de problemas mediados por um excesso de substancia p
DK99940199T DK1103243T3 (da) 1998-08-07 1999-08-05 Anvendelse af aryl(eller heteroaryl)azolylcarbinol-derivater til behandling af lidelser medieret af et overskud af substans P
AU54229/99A AU754124B2 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
PCT/ES1999/000255 WO2000007542A2 (es) 1998-08-07 1999-08-05 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p
TW088113353A TW445259B (en) 1998-08-07 1999-08-05 Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P
EP99940199A EP1103243B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives for the treatment of troubles mediated by an excess of substance p
KR1020017001560A KR100558506B1 (ko) 1998-08-07 1999-08-05 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도
CNB998109150A CN1151789C (zh) 1998-08-07 1999-08-05 芳基(或杂芳基)吡咯基甲醇的衍生物的应用
HU0105428A HUP0105428A3 (en) 1998-08-07 1999-08-05 Utilization of aryl or heteroaryl-azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p
CA002339661A CA2339661C (en) 1998-08-07 1999-08-05 Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p
PL99346221A PL193802B1 (pl) 1998-08-07 1999-08-05 Zastosowanie pochodnych arylo (lub heteroarylo) azolilokarbinoli do wytwarzania leku do leczenia zaburzeń wywoływanych nadmiarem substancji P
AT99940199T ATE257379T1 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
CZ2001412A CZ292065B6 (cs) 1998-08-07 1999-08-05 Použití derivátů aryl (nebo heteroaryl)azolylkarbinolů pro přípravu léčiv k léčení chorob zprostředkovaných přebytkem substance P
US09/762,079 US6518295B1 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
DE69914085T DE69914085T8 (de) 1998-08-07 1999-08-05 Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
TR2001/00378T TR200100378T2 (tr) 1998-08-07 1999-08-05 P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
RU2001106644/15A RU2223116C2 (ru) 1998-08-07 1999-08-05 Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
JP2000563228A JP2002522359A (ja) 1998-08-07 1999-08-05 過剰のサブスタンスｐによって仲介される障害の処置用医薬の製造におけるアリール（またはヘテロアリール）アゾリルカルビノール誘導体の使用
NZ509645A NZ509645A (en) 1998-08-07 1999-08-05 Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P
ZA200100867A ZA200100867B (en) 1998-08-07 2001-01-31 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P.
NO20010634A NO20010634L (no) 1998-08-07 2001-02-06 Anvendelse av derivater av aryl (eller heteroaryl)azolylkarbinol ved fremstilling av et medikament for behandling av forstyrrelser formidlet av et overskudd av substans P
IL14129501A IL141295A0 (en) 1998-08-07 2001-02-07 Use of derivatives of aryl (or heteroaryl) azolycarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance p

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Publications (2)

Publication Number Publication Date
ES2150378A1 true ES2150378A1 (es) 2000-11-16
ES2150378B1 ES2150378B1 (es) 2001-07-01

Family

ID=8304839

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801708A Expired - Fee Related ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99940199T Expired - Lifetime ES2213380T3 (es) 1998-08-07 1999-08-05 Uso de derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de los trastornos mediados por un exceso de substancia p.

Country Status (26)

Country Link
US (1) US6518295B1 (es)
EP (1) EP1103243B1 (es)
JP (1) JP2002522359A (es)
KR (1) KR100558506B1 (es)
CN (1) CN1151789C (es)
AR (1) AR019999A1 (es)
AT (1) ATE257379T1 (es)
AU (1) AU754124B2 (es)
BR (1) BR9912807A (es)
CA (1) CA2339661C (es)
CO (1) CO5080747A1 (es)
CZ (1) CZ292065B6 (es)
DE (1) DE69914085T8 (es)
DK (1) DK1103243T3 (es)
ES (2) ES2150378B1 (es)
HU (1) HUP0105428A3 (es)
IL (1) IL141295A0 (es)
NO (1) NO20010634L (es)
NZ (1) NZ509645A (es)
PL (1) PL193802B1 (es)
PT (1) PT1103243E (es)
RU (1) RU2223116C2 (es)
TR (1) TR200100378T2 (es)
TW (1) TW445259B (es)
WO (1) WO2000007542A2 (es)
ZA (1) ZA200100867B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080908A1 (es) * 2001-04-06 2002-10-17 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias
WO2003004022A1 (es) * 2001-07-06 2003-01-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de la incontinencia urinaria
ES2335181A1 (es) * 2006-02-10 2010-03-22 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1981497A2 (en) * 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
CN101528710B (zh) 2006-10-19 2012-11-07 弗·哈夫曼-拉罗切有限公司 氨基甲基-4-咪唑类
KR101176700B1 (ko) 2006-11-02 2012-08-23 에프. 호프만-라 로슈 아게 미량 아민 결합된 수용체의 조절자로서 치환된 2-이미다졸
AU2007321376A1 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2101762B1 (en) 2006-12-13 2011-05-18 F. Hoffmann-La Roche AG Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
JP2010531837A (ja) 2007-07-02 2010-09-30 エフ．ホフマン−ラ ロシュ アーゲー 微量アミン関連レセプター（ｔａａｒ）に対して良好な親和性を有する２−イミダゾリン
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CN101784515A (zh) 2007-08-03 2010-07-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体的吡啶甲酰胺和苯甲酰胺衍生物
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20100291151A1 (en) * 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
SG10201913878YA (en) 2016-03-17 2020-03-30 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289380A1 (fr) * 1987-04-10 1988-11-02 Laboratorios Del Dr. Esteve, S.A. Dérivés d'aryl-hétéroaryl carbinols avec activité analgésique
EP0699674A1 (en) * 1994-07-22 1996-03-06 Eli Lilly And Company 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders
WO1998024438A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
WO1998024447A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289380A1 (fr) * 1987-04-10 1988-11-02 Laboratorios Del Dr. Esteve, S.A. Dérivés d'aryl-hétéroaryl carbinols avec activité analgésique
EP0699674A1 (en) * 1994-07-22 1996-03-06 Eli Lilly And Company 1-Aryl-2-acetylamidopentanone derivatives for use as tachykinin receptor antagonists
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders
WO1998024438A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
WO1998024447A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
WO1998024445A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating schizophrenic disorders

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080908A1 (es) * 2001-04-06 2002-10-17 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias
ES2174756A1 (es) * 2001-04-06 2002-11-01 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
WO2003004022A1 (es) * 2001-07-06 2003-01-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril(o heteroaril)azolilcarbinoles para el tratamiento de la incontinencia urinaria
ES2180449A1 (es) * 2001-07-06 2003-02-01 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
ES2335181A1 (es) * 2006-02-10 2010-03-22 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas.

Also Published As

Publication number Publication date
PL346221A1 (en) 2002-01-28
CA2339661C (en) 2006-10-17
HUP0105428A3 (en) 2003-01-28
BR9912807A (pt) 2001-10-16
CN1151789C (zh) 2004-06-02
ATE257379T1 (de) 2004-01-15
RU2223116C2 (ru) 2004-02-10
DE69914085T8 (de) 2005-04-21
KR20010079616A (ko) 2001-08-22
ES2150378B1 (es) 2001-07-01
ZA200100867B (en) 2001-08-16
AR019999A1 (es) 2002-03-27
CN1317966A (zh) 2001-10-17
AU754124B2 (en) 2002-11-07
NO20010634L (no) 2001-04-06
WO2000007542A3 (es) 2000-05-11
HUP0105428A2 (hu) 2002-05-29
TR200100378T2 (tr) 2001-06-21
NO20010634D0 (no) 2001-02-06
TW445259B (en) 2001-07-11
CZ2001412A3 (cs) 2001-08-15
EP1103243A2 (en) 2001-05-30
AU5422999A (en) 2000-02-28
NZ509645A (en) 2003-01-31
CO5080747A1 (es) 2001-09-25
JP2002522359A (ja) 2002-07-23
DK1103243T3 (da) 2004-05-03
KR100558506B1 (ko) 2006-03-07
ES2213380T3 (es) 2004-08-16
CZ292065B6 (cs) 2003-07-16
EP1103243B1 (en) 2004-01-07
IL141295A0 (en) 2002-12-01
CA2339661A1 (en) 2000-02-17
US6518295B1 (en) 2003-02-11
WO2000007542A2 (es) 2000-02-17
PT1103243E (pt) 2004-05-31
PL193802B1 (pl) 2007-03-30
DE69914085D1 (de) 2004-02-12
DE69914085T2 (de) 2004-11-25

Similar Documents

Publication Publication Date Title
ES2150378A1 (es) Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
EP1719761A4 (en) NEW HETEROCYCLIC CONNECTION
IL190780A0 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
BR9802005A (pt) Derivado de pirazola tricìclico
DE60106641D1 (de) Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
ES2150353A1 (es) Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
GB9413975D0 (en) New heterobicyclic derivatives
MY118796A (en) 1,2,4-triazolo [4,3-b] pyrido [3,2-d] pyridazine derivatives and pharmaceutical compositions containing them
HUP0102543A2 (hu) Szexuális rendellenességek kezelésére alkalmas, cGMP PDE inhibitor hatású pirazolopiramidinon-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP9802224A1 (hu) Pirazolszármazékok, eljárás előállításukra, és gyógyszerként történő alkalmazásuk
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
FI961412A0 (fi) Sigma- ja/tai 5HTiA-reseptoreiden suhteen aktiiviset tetrahydropyridiini- (tai 4-hydroksipiperidiini)alkyyliatsolit
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
HUP0004477A2 (hu) Herbicid hatású 3-(1,2-benzizotiazol- vagy-izoxazol-5-il)-csoporttal helyettesített pirimidinszármazékok, intermedierjeik, előállításuk és alkalmazásuk
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
IL99305A (en) 4-substituted dihydropyrido [4,3-d]pyrimidines their preparation and analgesic and topical antiinflammatory compositions containing them for the treatment of skin disorders
ATE161535T1 (de) 6,11-dihydro-5h-pyrido(2,3-b)(1,5)benzodiazepin 5-one und thione und ihre verwendung für die vorbeugung oder behandlung von aids
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
ES2137136A1 (es) Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica.
HK1018782A1 (en) 2,3-benzodiazepine derivatives their preparation as well as the intermediates and their use as medicaments
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
TW200407315A (en) Pyrimidine derivatives
WO2002024641A1 (fr) Composes indol tricycliques possedant une affinite pour le recepteur de serotonine

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20001116

Kind code of ref document: A1

Effective date: 20001116

FD2A Announcement of lapse in spain

Effective date: 20180807